Meetings

VivaTech is one of Europe's leading technology and startup events; USP and FAPESP will take researchers and disruptive technologies to the event in the areas of health, agriculture, sustainability, and artificial intelligence.

Conservation experts are uniting to protect some of the world’s most endangered species and their habitats.

 

The Nature FIRST project launched in 2022, with University of Staffordshire and 11 global partners working together to improve biodiversity and protect species being threatened by human activity across Europe – including wolf, bear, lynx, and sturgeon.

 

An event on 25 – 26 June 2025 will mark the culmination of the £4.9m Horizon Europe funded project, bringing together leading conservationists, researchers, policymakers, and innovators to exchange strategies and drive impactful solutions for biodiversity conservation.

On May 26, the Institut national de la recherche scientifique (INRS) welcomed a European delegation from the Extreme Light Infrastructure (ELI), marking a significant milestone in strengthening scientific ties between Canada and Europe in the field of high-intensity laser science. The visit was part of a cross-Canada tour organized in partnership with the Hungarian and Czech  Embassies, host countries of the ELI facilities. 

At the heart of this meeting was a shared commitment to advancing ultrafast laser science and training the next generation of highly skilled researchers. INRS, internationally recognized for its work in advanced materials, nanotechnology, photonics, telecommunications, and sustainable energy, found in ELI a natural partner with world-class research infrastructure. 

As antibiotic resistance reaches critical levels worldwide, the 8th World Congress on Targeting Phage Therapy (June 10–11, 2025) returns to Berlin, bringing together over 75 international speakers and contributors from 27 countries. The congress offers the most comprehensive scientific and clinical update on phage therapy—a once-overlooked solution now at the forefront of next-generation medicine.

On May 22-23, a select group of scientists from around the world gathered in the small town of Acciaroli in the Cilento-Salerno region of Italy to review a decade’s worth of research in the ongoing Cilento Initiative on Aging Outcomes (CIAO), a longitudinal study of local residents 100 years and older.   

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center.